ArticleFrontiers in immunology2021
Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19.International journal of molecular sciences · 2023Pooled it
- Adenosine A2AR in viral immune evasion and therapy: unveiling new avenues for treating COVID-19 and AIDS.Molecular biology reports · 2024Review
- Purinergic signaling: decoding its role in COVID-19 pathogenesis and promising treatment strategies.Inflammopharmacology · 2023Review
- An interaction-based drug discovery screen explains known SARS-CoV-2 inhibitors and predicts new compound scaffolds.Scientific reports · 2023Article
- Integrated multiomics analysis to infer COVID-19 biological insights.Scientific reports · 2023Article
- Safety of Adenosine for the Treatment of Supraventricular Tachycardia in Hospitalized Patients with COVID-19 Pneumonia.Journal of clinical medicine · 2023Article
- Gain- and Loss-of-FunctionCells · 2022Article
- Effects of Purinergic Receptor Deletion or Pharmacologic Modulation on Pulmonary Inflammation in Mice.ACS pharmacology & translational science · 2022Article
- Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices.International journal of pharmaceutics · 2022Review
- Alterations in CD39/CD73 axis of T cells associated with COVID-19 severity.Journal of cellular physiology · 2022Article
- Longitudinal analyses reveal distinct immune response landscapes in lung and intestinal tissues from SARS-CoV-2-infected rhesus macaques.Cell reports · 2022Article
- Possible role of pannexin 1 channels and purinergic receptors in the pathogenesis and mechanism of action of SARS-CoV-2 and therapeutic potential of targeting them in COVID-19.Life sciences · 2022Review
- High levels of extracellular ATP lead to different inflammatory responses in COVID-19 patients according to the severity.Journal of molecular medicine (Berlin, Germany) · 2022Article
- Therapeutic Targeting of Hypoxia-A2-Adenosinergic Pathway in COVID-19 Patients.Physiology (Bethesda, Md.) · 2022Article
- Network pharmacology reveals multitarget mechanism of action of drugs to be repurposed for COVID-19.Frontiers in pharmacology · 2022Article
- Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients.Frontiers in immunology · 2022Article
- Nanomaterials as Promising Theranostic Tools in Nanomedicine and Their Applications in Clinical Disease Diagnosis and Treatment.Nanomaterials (Basel, Switzerland) · 2021Review
- Integration Analysis of Pharmacokinetics and Metabolomics to Predict Metabolic Phenotype and Drug Exposure of Remdesivir.Frontiers in pharmacology · 2021Article
- The Dynamic Immunological Parameter Landscape in Coronavirus Disease 2019 Patients With Different Outcomes.Frontiers in immunology · 2021Article
- DAMPening COVID-19 Severity by Attenuating Danger Signals.Frontiers in immunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lack of specific antiviral treatment for COVID-19 has resulted in long hospitalizations and high mortality rate. By harnessing the regulatory effects of adenosine on inflammatory mediators, we have instituted a new therapeutic treatment with inhaled adenosine in COVID-19 patients, with the aim of reducing inflammation, the onset of cytokine storm, and therefore to improve prognosis. The use of inhaled adenosine in COVID19 patients has allowed reduction of length of stay, on average 6 days. This result is strengthened by the decrease in SARS-CoV-2 positive days. In treated patients compared to control, a clear improvement in PaO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.